SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001683168-19-003516
Filing Date
2019-11-08
Accepted
2019-11-08 17:30:21
Documents
2
Period of Report
2019-11-07

Document Format Files

Seq Description Document Type Size
1 ownership.html 3  
1 ownership.xml 3 2907
2 POWER OF ATTORNEY gumulka_f3-poa.htm EX-24.1 4667
  Complete submission text file 0001683168-19-003516.txt   8953
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185 X701
CNS Pharmaceuticals, Inc. (Issuer) CIK: 0001729427 (see all company filings)

IRS No.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O CNS PHARMACEUTICALS, INC. 2100 WEST LOOP SOUTH STE 900 HOUSTON TX 77027
Business Address
Gumulka Jerzy (Reporting) CIK: 0001793252 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39126 | Film No.: 191205166